Thyrocare Technologies Ltd - 539871 - Announcement under Regulation 30 (LODR)-Investor Presentation
We are forwarding a copy of Presentation on Quarterly Results of our company for the quarter / half year ended 30-09-2021.15-11-2021
15-11-2021
Thyrocare Technologies Ltd - 539871 - Financial Results As On September 30,2021
This is to inform you that the Board of Directors of the Company, at their meeting held today, approved the unaudited Financial Results (Stand-alone and Consolidated) for the Quarter / Half year ended September 30, 2021.13-11-2021
Thyrocare Technologies Ltd - 539871 - Board Meeting Outcome for Outcome Of Board Meeting Held Today, 13Th November 2021
This is to inform you that the Board of Directors of the Company, at their meeting held today, approved the unaudited Financial Results (Stand-alone and Consolidated) for the Quarter / Half year ended September 30, 2021.13-11-2021
Thyrocare Technologies Ltd - 539871 - Board Meeting Intimation for : Prior Intimation Under Regulation 29 (1) (A) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Thyrocare Technologies Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/11/2021 ,inter alia, to consider and approve Pursuant to Regulation 29 (1) (a) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to intimate that a meeting of our Board of Directors of the Company will be held on Saturday, November 13, 2021, inter alia, to consider and approve Unaudited Stand-alone and Consolidated Financial Results of the Company for the quarter / half year ended September 30, 2021.02-11-2021
Thyrocare Technologies Ltd - 539871 - Board Meeting Outcome for Outcome Of Board Meeting- 27-10-2021- Pursuant To Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
This is to inform you that the Board of Directors of the Company, at their meeting held today: 1) Approved the Audited Special Purpose Consolidated financial statements of the Company as on 30th June 2021 2) Noted the Management Accounts of the Company (unaudited, not reviewed) as on 30th September 2021 which would be shared with API Holdings Limited and their merchant bankers. 3) Approved the proposal, based on the recommendation of the Audit Committee, to enter into an agreement for outsourcing the processing of samples and generating report, with API Holdings Ltd., who are a Related Party under statutory provisions.27-10-2021
Thyrocare Technologies Ltd - 539871 - Shareholding for the Period Ended September 30, 2021
Thyrocare Technologies Ltd has submitted to BSE the Shareholding Pattern for the Period Ended September 30, 2021. For more details, kindly Click here21-10-2021
Thyrocare Technologies Ltd - 539871 - Statement Of Investor Complaints For The Quarter Ended September 2021
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- RAMJEE DORAIDesignation :- Company Secretary and Compliance Officer11-10-2021
Thyrocare Technologies Ltd - 539871 - Board Meeting Outcome for Disclosure Under Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015
The Board of Directors of the Company in their meeting held on 6 October 2021 have, inter alia, taken the following decisions: (a) Appointment of Dr. Dhaval Rajesh Shah as additional Director (b) Appointment of Ernst & Young as Internal Auditors of the Company for the year 2021-22 (c) Issue and allotment of 28,913 equity shares to the eligible employees under ESOP Scheme.07-10-2021
Thyrocare Technologies Q2 PAT may dip 2.9% YoY to Rs 41.8 cr: Prabhudas Lilladher
Net Sales are expected to increase by 1.6 percent Y-o-Y (down 5.7 percent Q-o-Q) to Rs 155.6 crore, according to Prabhudas Lilladher.06-10-2021
Thyrocare Technologies Ltd - 539871 - Closure of Trading Window
Pursuant to the provisions of SEBI (Prohibition of Insider Trading) Regulations 2015, as amended, and in accordance with the Company's Code relating to prohibition of insider trading, the trading window of the Company will remain closed for trading in Company's equity shares for Directors / Designated Employees / Connected Persons covered by the said Code, with effect from October 01, 2021, and would be re-opened after 48 hours of date of announcement / declaration of Unaudited Financial Results for the Quarter and half year ended September 30, 2021.30-09-2021